Global Blood Therapeutics, Inc. (GBT)
Chart Events
Performance Outlook
| Previous Close | 31.57 |
| Open | 31.48 |
| Bid | 28.01 x 900 |
| Ask | 31.33 x 1200 |
| Day's Range | 30.74 - 32.10 |
| 52 Week Range | 25.11 - 63.03 |
| Volume | 979,419 |
| Avg. Volume | 1,175,785 |
| Market Cap | 1.922B |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.05 |
| Earnings Date | Nov 03, 2021 - Nov 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.47 |
- Simply Wall St.
Investors bid Global Blood Therapeutics (NASDAQ:GBT) up US$209m despite increasing losses YoY, taking five-year CAGR to 11%
It hasn't been the best quarter for Global Blood Therapeutics, Inc. ( NASDAQ:GBT ) shareholders, since the share price...
- TipRanks
Investing in These 2 Stocks Could Double Your Money, Say Analysts
Investors are constantly searching for the next big winner. We mean the stocks that are on track to see explosive growth, handsomely rewarding the investors that managed to get onboard at the right time. But how are investors supposed to know when it’s time to snap up the right stock? When first approaching this task, investors will often turn to names during or on the heels of an impressive rally. However, Wall Street analysts note that this isn’t always the best move. Instead, the Street’s sea
- Benzinga
See Why Jefferies Sees Massive Upside In Global Blood Therapeutics
Jefferies initiated coverage of Global Blood Therapeutics Inc (NASDAQ: GBT) with a Buy rating and $68 price target. The analyst sees an upside of almost 145%. Oxbryta's implied sickle cell disease (SCD) market share is only 5%-6% at the stock's current valuation. Still, analyst Akash Tewari sees a 22% share and models $1.1 billion in peak sales for the drug in that indication. Related: Global Blood's Sickle Cell Medicine Under FDA Review For Expanded Use. Meanwhile, Tewari calls GBT601 "the most
